

11. Ferrari SL et al. Diagnosis and management of bone fragility in diabetes: an emerging challenge. *Osteoporosis International*, 2018; 29(12): p. 2585–2596.
12. Leslie WD et al. TBS (trabecular bone score) and diabetes-related fracture risk. *J Clin Endocrinol Metab*, 2013; 98(2): p. 602–609.
13. Ebrahimpur M et al. Effect of diabetes on BMD and TBS values as determinants of bone health in the elderly: Bushehr Elderly Health program. *Journal of Diabetes & Metabolic Disorders*, 2019; 18(1): p. 99–106.
14. Jackuliak P et al. Good long-term glycemic compensation is associated with better trabecular bone score in postmenopausal women with type 2 diabetes. *Physiol Res*, 2019; 68(Suppl 2): p. S149–s156.
15. Schwartz AV et al. Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes. *Jama*, 2011; 305(21): p. 2184–2192.
16. Leslie WD et al. Type 2 diabetes and bone. *J Bone Miner Res*, 2012; 27(11): p. 2231–2237.
17. Giangregorio LM et al. FRAX underestimates fracture risk in patients with diabetes. *J Bone Miner Res*, 2012; 27(2): p. 301–308.
18. Keegan TH et al. Effect of alendronate on bone mineral density and biochemical markers of bone turnover in type 2 diabetic women: the fracture intervention trial. *Diabetes Care*, 2004; 27(7): p. 1547–1553.
19. Cummings SR et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. *Jama*, 1998; 280(24): p. 2077–2082.
20. Dagdelen S et al. Influence of type 2 diabetes mellitus on bone mineral density response to bisphosphonates in late postmenopausal osteoporosis. *Advances in Therapy*, 2007; 24(6): p. 1314–1320.
21. Inoue D et al. Efficacy and Safety of Risedronate in Osteoporosis Subjects with Comorbid Diabetes, Hypertension, and/or Dyslipidemia: A Post Hoc Analysis of Phase III Trials Conducted in Japan. *Calcified Tissue International*, 2016; 98(2): p. 114–122.
22. Johnell O et al. Associations Between Baseline Risk Factors and Vertebral Fracture Risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study. *Journal of Bone and Mineral Research*, 2004; 19(5): p. 764–772.
23. Schwartz AV et al. Teriparatide in patients with osteoporosis and type 2 diabetes. *Bone*, 2016; 91: p. 152–158.
24. Langdahl BL et al. Real-world effectiveness of teriparatide on fracture reduction in patients with osteoporosis and comorbidities or risk factors for fractures: Integrated analysis of 4 prospective observational studies. *Bone*, 2018; 116: p. 58–66.
25. Zebaze R et al. Denosumab Reduces Cortical Porosity of the Proximal Femoral Shaft in Postmenopausal Women With Osteoporosis. *J Bone Miner Res*, 2016; 31(10): p. 1827–1834.
26. Hayakawa N, Suzuki A. Diabetes mellitus and osteoporosis. Effect of antidiabetic medicine on osteoporotic fracture. *Clin Calcium*, 2012; 22(9): p. 1383–1390.
27. Jackuliak P et al. Effect of antidiabetic treatment on bone. *Physiol Res*, 2019; 68(Suppl 2): p. S107–s120.
28. Paul T, Thomas N. Impact of oral antidiabetic agents on bone metabolism. *Indian Journal of Medical Research*, 2015; 141(4): p. 385–388.
29. McCarthy AD, Cortizo AM, Sedlinsky C. Metformin revisited: Does this regulator of AMP-activated protein kinase secondarily affect bone metabolism and prevent diabetic osteopathy. *World Journal of Diabetes*, 2016; 7(6): p. 122–133.
30. Gilbert MP, Pratley RE. The Impact of Diabetes and Diabetes Medications on Bone Health. *Endocrine Reviews*, 2015; 36(2): p. 194–213.
31. Vestergaard P et al. Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. *Diabetologia*, 2005; 48(7): p. 1292–1299.
32. Schwartz AV. Diabetes and Metabolism of Bone, in ENDO 2017: Meet-The-Professor Endocrine Case Management, J. Leahy and A. Danoff, Editors. 2017: Washington DC. p. 63–65.
33. Palermo A et al. Oral anti-diabetic drugs and fracture risk, cut to the bone: safe or dangerous? A narrative review. *Osteoporos Int*, 2015; 26(8): p. 2073–2089.
34. Lecka-Czernik B. Safety of Anti-Diabetic Therapies on Bone. *Clinical Rev Bone Miner Metab.*, 2013; 11(1): p. 49–58.
35. Molinuevo MS et al. Effect of metformin on bone marrow progenitor cell differentiation: In vivo and in vitro studies. *Journal of Bone and Mineral Research*, 2010; 25(2): p. 211–221.
36. Sundararaghavan V et al. Diabetes and bone health: latest evidence and clinical implications. *Therapeutic Advances in Musculoskeletal Disease*, 2017; 9(3): p. 67–74.
37. Melton LJ et al. Fracture risk in type 2 diabetes: update of a population-based study. *J Bone Miner Res*, 2008; 23(8): p. 1334–1342.
38. Russo GT et al. Fracture Risk in Type 2 Diabetes: Current Perspectives and Gender Differences. *International Journal of Endocrinology*, 2016; 2016: p. 1615735.
39. Mehta S. Comparative Safety of Oral Antidiabetic Therapy on Risk of Fracture in Patients with Diabetes, in American Diabetes Association 2014 Scientific Sessions; 2014: p. 165–OR.
40. Medscape Sulfonylureas May Up Fracture Risk in Diabetes, Along With TZDs. 2014.
41. Mieczkowska A et al. Thiazolidinediones induce osteocyte apoptosis by a G protein-coupled receptor 40-dependent mechanism. *J Biol Chem*, 2012; 287(28): p. 23517–23526.
42. Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. *Canadian Medical Association Journal*, 2009; 180(1): p. 32–39.
43. Ceccarelli E et al. Beyond Glycemic Control in Diabetes Mellitus: Effects of Incretin-Based Therapies on Bone Metabolism. *Frontiers in Endocrinology*, 2013; 4(73): p. 1–12.
44. Monami M et al. Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials. *Diabetes Care*, 2011; 34(11): p. 2474–2476.
45. Nauck MA et al. Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin: A randomized, 52-week, double-blind, active-controlled noninferiority trial. *Diabetes Care*, 2011; 34(9): p. 2015–2022.
46. List JF et al. Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes. *Diabetes Care*, 2009; 32(4): p. 650–657.
47. Ljunggren Ö et al. Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin. *Diabetes, Obesity and Metabolism*, 2012; 14(11): p. 990–999.
48. Kohan DE et al. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. *Kidney International*, 2014; 85(4): p. 962–971.
49. Watts NB et al. Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus. *The Journal of Clinical Endocrinology and Metabolism*, 2016; 101(1): p. 157–166.
50. Campos Pastor MM et al. Intensive insulin therapy and bone mineral density in type 1 diabetes mellitus: a prospective study. *Osteoporos Int*, 2000; 11(5): p. 455–459.
51. Fowlkes JL et al. Contributions of the Insulin/Insulin-Like Growth Factor-1 Axis to Diabetic Osteopathy. *Journal of diabetes & metabolism*, 2011; 1(3): p. S1–003.
52. Zhukouskaya VV et al. Bone Health in Type 1 Diabetes: Where We Are Now and How We Should Proceed. *Advances in Endocrinology*, 2014; 2014: p. 12.
53. Kanazawa I et al. Relationships between serum adiponectin levels versus bone mineral density, bone metabolic markers, and vertebral fractures in type 2 diabetes mellitus. *Eur J Endocrinol*, 2009; 160(2): p. 265–273.
54. Chandran M. Diabetes Drug Effects on the Skeleton. *Calcified Tissue International*, 2017; 100(2): p. 133–149.
55. Ferrari S. Diabetes and Bone. *Calcif Tissue Int*, 2017; 100(2): p. 107–108.
56. Quandt SA et al. Predictors of Falls in a Multiethnic Population of Older Rural Adults With Diabetes. *The journals of gerontology. Series A, Biological sciences and medical sciences*, 2006; 61(4): p. 394–398.